



INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A REVIEW ON ANKYLOSING SPONDYLITIS

Author name: Mr. Nirpal Kunal , Ms. Jadhav Pallavi

Name of department: Pharmacology

Abstract

Ankylosing spondylitis (AS), a frequent kind of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mostly affects the joints of the spine, producing severe, persistent pain and, in severe cases, spine fusion. In the recent decade, significant progress has been made in terms of pathophysiology and therapy. Innate cytokines and immune cells have been studied. Human leukocyte antigen (HLA)B27 and the interleukin 23/17 axis are thought to be important in the pathophysiology of AS. The pathophysiology of AS, on the other hand, is unknown. The present study looked at the origin and pathophysiology of AS, as well as how it affects people. cytokine pathways and genome-wide association studies The present pharmacological and surgical landscape was also described in this study. Treatment will be followed by a discussion of prospective future therapy. Nonsteroidal anti-inflammatory drugs (NSAIDs) are currently the first-line drug treatment for inflammatory symptoms. Treatment with NSAIDs, on the other hand, has only a symptomatic effect and is unlikely to change the course of the disease. course. Second-line therapies, such as corticosteroids and other disease-modifying antirheumatic medications, are used for symptoms that are resistant to NSAIDs, although they are of little efficacy. Emerging biological treatments are aimed at the inflammatory processes that cause AS, and hence have the potential to improve the condition. In addition to symptom alleviation, the illness process is aided.

Keyword

Ankylosing spondylitis, HLA B-27, NSAID's, Corticosteroid's, Thoracolumbar kyphosis

Introduction

A ceaseless type of common pain what influences, for the utmost part, the spine and in numerous egging combinations of the vertebrae. Guys have a advanced circumstance than ladies 2-3:1 proportion. Further immature age gathering is decreasingly told. This generally influences the vital shell, still, it might likewise connected with fringe joint inflammation and extra-articular features. The morning of the sickness is steady and described by aseptic vexation at the SIJs. It causes handicap and lowered particular satisfaction. The most extensively honored finding of AS is acute frontal uveitis which is plant in 20-25 of cases. Eye and inside issues may likewise do. The primary suggestions in eye are torment, lowered imprint of light, photophobia, and expanded lacrimation. The firmness of the told joints intensifies after some time. AS is discovered worldwide. This has a place with spondyloarthropathy class of Rheumatic affections. There's no result for ankylosing spondylitis. Hostile to rheumatic specifics are less full of feeling and birth treatments are compelling. In the lesser part of the cases, medical procedure is the main way. This check composition talked about ankylosing spondylitis, its weight, pathogenesis, analysis, and directors. (1)

Spondyloarthropathy refers to a miscellaneous group of rheumatic conditions that present common clinical and inheritable features, which are classified as supplemental or axial (axSpA) grounded on what corridor of the body are generally affected. Ankylosing spondylitis (AS), a type of Gym, is an autoimmune complaint that substantially involves chine joints, sacroiliac joints (SJs) and their conterminous soft tissues, similar as tendons and ligaments. In further advanced cases, this inflammation can lead to fibrosis and calcification, performing in the loss of inflexibility and the emulsion of the chine, suggesting "bamboo" with an immobile position. The main clinical instantiations include back pain and progressive spinal severity as well as inflammation of the hips, shoulders, supplemental joints and fritters/ toes. In addition, there are extra-articular instantiations, similar as acute anterior uveitis and seditious bowel complaint (ID). Still, the extra-articular instantiations differ between East Asian and Caucasian populations. In a study involving 988 cases with ankylosing spondylitis in east Asia, only 0.4 advanced seditious bowel complaint.(2)

Still, in some analyses performed in Western countries, 5-10 of cases with AS present with seditious bowel complaint.(3)(4) The frequency of AS has a clear correlation with the mortal leukocyte antigen (HLA)-B27 positive rate in specific populations. Studies have revealed that in HLA-B27-positive populations, the frequency rate of AS is 5-6%.(5) In a 2009 public check in the United States, the frequency of HLA-B27-positive populations varied in different ethnical communities, with 7.5, 4.6, and 1.1 in non-Hispanic whites, Mexican-Americans, and non-Hispanic lacks, independently.(6) "In the literature, males reportedly regard for the vast maturity of cases of AS, while the prevalence among men and women is analogous in nonradiographic axial spondyloarthropathy (nr-axSpA), which refers to individualities meeting clinical criteria for axSpA without radiological substantiation of sacroillitis. A meta-analysis including eight studies including 2 236 cases with AS and 1 242 cases with nr-axSpA revealed that males reckoned for 70.4 of AS cases and 46.5 of cases with nr-axSpA.(7) Inheritable vulnerability results have shown the following intermittent threat factors in different generations of cousins monozygotic (MZ) halves, 63 (17/27); first-generation cousins, 8.2 (441/5 390); second-generation cousins, 1.0 (8/834); and third-generation cousins, 0.7 (7/997).(8)

Available criteria sets are constantly used in clinical practice to help clinicians make judgments. Presently, the most extensively applied individual bracket of AS is the modified New York (mNY) criteria. In this bracket system, a case needs to meet at least one clinical criterion and the radiological opinion of AS. Another bracket is Amor criteria and European Spondyloarthropathy Study Group (ESSG) criteria for diagnosing AS. In 2012, AV Tubergen banded the different bracket criteria sets for AS and SpA.(9) In addition, the ASAS criteria, the dominant individual criteria for axSpA, have gained fashionability in Europe (2016 update of the ASAS-EULAR operation recommendations for axial spondyloarthritis). As clinicians sounded to have difficulty secerning AS and SpA, Joel D. Taurog established an algorithm for the opinion or rejection of axSpA.(10)

The confusion in opinion and lack of complaint-modifying rectifiers, including anti-TNF-a and anti-IL-17 treatment of AS, are largely due to the limited knowledge of the pathogenesis, which may involve impunity, heredity and other factors.

Its origin and pathogenesis are unknown, therefore diagnosing can be difficult. As a result, AS management and therapy are frequently inadequate. The rate of scientific and medical discovery is continually increasing. Bridging the knowledge gaps that are impeding development thorough understanding of the disease and, as a result, improved disease management Efforts to improve the predicament of the homeless Patients with AS benefit from a broad understanding of the condition. of pathogenesis, diagnosis, treatment, and natural progression and the disease's socioeconomic impact. An outline of these is provided below. Here you will find information about many elements of AS.(11)

Sign and symptoms

The sign and symptoms of AS include:

Pain and firmness mostly in lower back, bottom, mid-back, or neck.

*It worsens after rest

*Joint torment and swelling in bigger joints

*Ability to do work, & exercise decreases

*Irritation of differ organ like eye, skin, lungs, and GI tract

*The pain advances with loss of spinal versatility

*Ectasia of the sacral nerve root sheaths occurs less frequently.

* Irritation of the aorta, aortic valve insufficiency, or worsening of the heart's electrical conduction framework are all possible cardiovascular inclusions.

* Dynamic fibrosis of the upper part of the lung characterises lung inclusion.(12)

Historical perspective

The condition currently recognised as AS has afflicted humanity since antiquity, according to palaeopathological studies of Egyptian mummies.(13)(14) However, it was not until 1559 that what is thought to be the earliest historical description of AS was published in the literature. Realdo Colombo described two anatomical structures. In his novel De Re Anatomica, he depicts skeletons with AS-like deformities.(15)

More than a century after Colombo's founding, in 1693, Bernard Connor, an Irish doctor, described a disinterred human skeleton with a pronounced curvature in the spine. The ilium, sacrum, five lumbar, and ten lumbar vertebrae are also included. Five right and three left ribs, as well as thoracic vertebrae, emerged. must be fused at "the junctions," resulting in a single, continuous bone Connor then went on to explain the probable outcomes of the situation. The effects of spine curvature on movement and breathing during the a patient's entire life. (16)(17)(18) Other clinical descriptions of AS-like illnesses did not. The term did not reappear in the literature until the mid-eighteenth century. . This was reported by a number of doctors (Lyons, Adams, Todd, Hare, Brodie, Wilson, Brodhurst, Hilton, Von Thaden, Fagge, and Sturge). between the years 1831 and 1879 (19) However, according to reports, Adolph Strümpell in Russia (1893), Wladimir von Bechterew Pierre Marie in France (1898),(20) and in Germany (1897). Connor5 has been credited with being the first to describe AS. The term AS was coined by Bechterew's classic description of AS. Bechterew's disease is a term that is often used in Germany. Despite the fact that these anatomical and clinical descriptions were written in the early 1900s, AS was first recognised as a distinct disease entity, and the idea of AS was born. With the advent of roentgenology and other medical specialties, the field of ophthalmology has evolved. Science and medicine have progressed. Roentgenology was discovered by Wilhelm Conrad Roentgen, a German physicist, around the same time as Strümpell and Marie described AS (in 1895), but it wasn't used to diagnose or treat AS until the early 1920s.

Sacroiliitis is one of the roentgenographic symptoms of AS. Syndesmophytes were found in early disease and syndesmophytes in advanced disease. Krebs, Scott, Forestier, and Robert in Krebs, Scott, Forestier, and Robert in Krebs, Scott, Forestier, and Robert in Krebs, Scott 1930s.(21)(22) These descriptions aided in the clarification of the clinical situation. They are still used in the diagnosis and treatment of AS today. The disease's stage. By the mid-nineteenth century, radiological, epidemiological, and clinical data had revealed links between AS and a variety of diseases. Reiter's disease, psoriatic arthritis, and other types of arthritis Arthritis, arthropathies, and arthropathies linked to the intestine disease.(21)(22)(23) As a result, Moll et al proposed the notion of spondyloarthropathies (SpAs) as a group of interrelated illnesses with similar clinical and genetic characteristic that is different from rheumatoid arthritis (RA).(23) Perhaps the most important milestones in the history of AS and its relationship to the other SpAs were the findings of an infectious etiology and a genetic etiology. Asthma predisposition Medical historians look at the discovery of human leucocyte antigens as an example of the latter.(HLAs) in the 1940s and 1950s, as well as its later classification the major histocompatibility complex (MHC) in humans as the most significant contribution to our understanding of SpAs. Initially, an infectious etiology was hypothesised based on Perhaps there is a link between AS and Reiter's syndrome. The most well-known of the SpAs. Reiter's condition was first identified in 1916. Hans Reiter coined the term "non-gonococcal urethritis" to describe the condition. Dysentery can cause peripheral arthritis and conjunctivitis. 18 The link between dysentery, Shigella flexneri infection, and venereally acquired genitourinary infections was established by subsequent documenting of the syndrome after dysentery, Shigella flexneri infection, and venereally acquired genitourinary infections. Reiter's syndrome and a gastrointestinal or genitourinary infection that preceded it.(24)(25) In 1969, the term "reactive arthritis" was coined.(26)

Some of the clinical indications of AS (such as spondylitis and uveitis) were seen in patients with ReA, suggesting a link between the two disorders. The discovery of a high-altitude crater in 1973 backed up the theory. HLA-B27 is common in both AS and Reiter's syndrome. (19)(27)(28) It's been linked to ReA in clinical and genetic studies. It was postulated that AS could have an infectious etiology. In fact, Klebsiella pneumoniae and other intestinal illnesses Escherichia coli has been linked to the development of AS. in hosts who are genetically sensitive.(29)(30) In addition, observation The discovery of a close relationship between IBD and AS led to the hypothesis that a healthy gut Once the bacteria has been removed from the body, it may activate the immune system. The mucosal barrier had been breached.(31)

Etiology

AS develops as an autoimmune illness as a result of complicated interplay between hereditary and environmental variables. Despite the fact that tremendous progress has been made in the In some ways, the aetiology of AS has remained a mystery in recent decades. To date, research has identified a number of elements that may be linked to the causes of AS, including genetics, immunity, and environmental factors response, microbial infection are all examples of endocrine abnormality.

Genetic background

Genetic variables have been identified as important in the development of AS. Since the discovery of hereditary variables in AS, the link between AS and genetics has been a hot issue. in 1961, within families A total of ten twin investigations have yielded notable findings. monozygotic twins had a greater concordance rate (63%) than dizygotic twins. in the case of dizygotic twins (23 percent). The effects of genetics have been studied. Pathogenic variables have been recognised as contributing to approximately 90% of all cases. the variation in AS symptoms across the population.(32)(33)

Among the Major histocompatibility is one of the most critical genetic variables. HLA-B27 is an MHC class I allele that was found in 1973.(34) Despite the lack of a defined pathomechanism, HLA-B27 has been linked to a variety of diseases. With relation to the frequency of AS in various populations all throughout the world According to studies, 90–95 percent of AS sufferers are women. HLA-B27-positive patients account for 1%–2% of all HLA-B27-positive patients. Asthma develops in populations. This number has risen to 15%–20% in the last few years. Those who have a first-degree relative who is impacted.(35)(36) With relative risks of 94, 25, and 4 for first-, second-, and third-degree relatives, respectively, the family tendency of AS was notable.(37)The average age of onset was substantially lower in positive cases. HLAB27-negative patients had a greater rate of acute anterior uveitis, as with HLAB27-positive patients.(38) There is a lot of polymorphism in HLA-B27. So far, over 100 subtypes have been identified(39) including disparities in incidence rates among ethnic groups, particularly among African-Americans people of East Asian and Caucasian ancestry. As previously stated, HLA-B2705 (Caucasian) is the most common subtype in AS. HLA-B2704 (Chinese people), and HLA-B2702 (European populations). (Mediterranean peoples).(39)(40)(41)(42) HLAB2706 and HLA-B2709, on the other hand, appear to be unrelated to AS.(43)(44) HLA-B27-transgenic rat studies on 2 microglobulin (2m),(45) a noncovalent protein, show that genetic influences are not the only factor in the development of AS. component of the MHC-I complex, has demonstrated that an extra 2m Reduces HLA-B27 misfolding while promoting arthritis and spondylitis, implying that B27 misfolding is linked to intestinal inflammation. inflammation.(46) This result suggested that abnormal 2m could be a problem. In the development of AS, collaborate with HLA-B27, which could be beneficial. Protein misfolding hypotheses will be discussed and explained further in the part on pathogenesis. Even while HLA-B27 is the most prominent genetic component, its total contribution to AS heritability is just 20%,(47) showing that other genetic variables play a role in AS. With the state of genome-wide association research (GWASs) and Non-HLA-B27 and even non-HLA genes have been used in different technologies. In recent years, AS has been discovered; simply, the genetic.

The disparities between different ethnicities have been investigated, and in comparison to prior years HLA-B60 is linked to HLA-B27-negative individuals. AS makes you three to six times more susceptible to illness. (48) years old study In a study on a Taiwanese community, it was discovered that the interaction HLA-B60 or HLA-B27 might be a better marker for the disease. Susceptibility to AS is a risk. (49) HLA-B7,(50) HLA-B16, HLA-B35(51)(52) HLA-B35(51)(52) HLA-B38, and HLA-B39 (52) have also been linked to HLA-B27. With unclear mechanisms, negative AS has been found in people of many races. An initial correlation and independent replication of two novel loci were found in a study of 1000 AS patients and 1500 healthy people. In a North American context, AS, ERAP1 (also known as ARTS1), and IL23R are linked. The United States took a sample and offered preliminary evidence for a number of cases. Nonsynonymous single nucleotide polymorphisms in non-MHC genes (nsSNPs).(53) These research on non-HLA-B27 genes and SNPs revealed a variation in illness pathophysiology between ethnic groups, which may bring fresh insights into the condition AS etiology and therapy.

Immunological & microbial factors

AS appears to be linked to a number of autoimmune diseases, including IBD, anterior uveitis, and psoriasis, implying that they may share a genetic basis and immunological processes. The In AS, differences in immune cells and cytokines suggest immunological effects in the etiology of AS During the HLA-B27-positive T cells secreting tumour necrosis factor (TNF) producing cells were used as controls. , as well as interferon (IFN) , were said to be decreased. In AS, CD8+ T lymphocytes are present. Patients were more likely to produce IL-10.(54) Other discoveries have also been made. immunological factors on the development of AS, It will be described in the next part.

The innate immune system of the host is triggered by microbial infection, which leads to the development of AS. In a germ-free environment, (55) HLA-B27 transgenic rats failed to acquire SpA characteristics. When commensal bacteria were introduced into the system, this altered the germ-free models (56)(57) indicating potential interactions HLA-B27 interacts with the microbiota. The gut microbiome, also known as the microbiome of the intestines. There were considerable variances in the families Lachnospiraceae, Veillonellaceae, Prevotellaceae, Porphyromonadaceae, and Bacteroidaceae. in AS patients as compared to healthy individuals. (58) *Klebsiella pneumoniae* is an opportunistic pathogen in a healthy human intestine, and studies have shown that it might be an important aggravating factor in the AS autoimmune process. (59) The link between the faecal and gastrointestinal tracts has produced mixed findings. AS activity and microbiota burden, such as *Klebsiella pneumoniae*. Some researchers believe *Klebsiella pneumoniae* influences AS development indirectly through interactions with HLAB27. (60) In addition, part of the reason for gut microbiota infection is the immunological deficit caused by a lack of certain immune components, resulting in immune dysfunction responses of higher potency and longer time span. (61)

Pathogenesis

The pathophysiology of AS remains a mystery. Inflammatory histology, elevated serum levels of IgA and acute phase reactants, and the close relationship between HLA-B27 and AS all point to immune-mediated mechanisms. There is no one agent. Although a specific incident has been recognised as the origin of the illness, The interdependence of AS, ReA, and IBD shows that It's possible that intestinal bacteria are involved (19)(62)

MHC Genetic

The HLA complex, commonly known as the human MHC, is a group of cell-surface proteins that play a role in the process of acquired immunity. The MHC gene family is divided into three subgroups: class I, II, and III. HLA-A, HLA-B, and HLA-C are all encoded by MHC class I. It's found on all nucleated human cells and platelets. TCR (T cell receptor) epitopes on the surface of cytotoxic T cells T lymphocytes (CTLs) are a kind of white blood cell. (63) The MHC class I heterodimer subgroup A polymorphic heavy chain is present. There are three links in the chain. 1, 2, and 3 are the domains. The 1 domain has non covalent connections. 2m is a non-MHC molecule, whereas 3 crosses the plasma. T cells' CD8 co receptor interacts with the membrane. (64)(65) Peptides of 8–10 amino acids can be linked by the MHC class I complex. one cleft spaced by both 1 and 2 acids in length, resulting to Immune responses are initiated and propagated in this way. (65)(66) A stable MHC molecule must be correctly packed and folded in the cell organelle endoplasmic reticulum (ER) under the control of the cell organelle endoplasmic reticulum (ER). Chaperones (calreticulin and tapasin) provide guidance. (63) Although the MHC class in its original form There is one heavy chain in I, and there are three in total. various MHCI structures, including cell-surface HLAB27 MHC I homodimers, as well as intracellular and exosomal MHC I dimers, have been identified. (67) These elements may have different pathophysiological functions & processes.

HLA-B27

The most important gene that predisposes an individual to AS is HLA-B27, which belongs to the MHC-I surface protein expressed by the MHC B gene on chromosome 6. HLA-B27 human T immunocytes are given peptide antigens. It is regarded to be a crucial part of the body's defensive system. AS is connected to inflammatory illnesses such arthritis and rheumatoid arthritis. a research paper around 7500 endogenous peptides were evaluated by the HLA–B27 allotypes (HLA–B2702 to HLA–B2708) are the eight most

common HLA-B27 allotypes. HLA-B2709), implying that binding to a consensus and selection There were major parallels and variances between the themes. different allotypes of HLA-B27 (68) The HLA-B27-HLA-B27-HLA-B27-HLA-B AS has not yet been completely clarified, despite its widespread use. acknowledged that HLA-complete B27's intracellular process It is necessary to think about formation. There are a few that are prevalent. theories about the mechanism, such as the theory that arthritogenic peptide, hypothesis of misfolding, hypothesis of molecular mimicry, as well as the cell-surface hypothesis Homodimer of HLA B27. The mature HLA-B27 complex is a quaternary structure made up of three key elements. HLA-function B27's depends on its correct assembly and folding in the ER. Following that, HLA-B27 is made up of free heavy chains that are non covalently connected and folded with 2m and an antigenic peptide. followed by trimolecular transport to the cell surface complex.(69) HLAB27, on the other hand, shows a proclivity towards misfolding, resulting in dimers and even multimers(70); Its structure may be the source of distinctive alterations. cysteine (C) is present at sites 67 (C67), 101 (C101), and 164. (C164), together with 325 (C325). (71) HLA-B27 would be useless if it wasn't folded correctly. just created and delivered to the cell surface Heavy chain homodimers are homodimers. The disorder is linked to HLAB27 structures, including HLAB2705, HLAB2704, and HLAB2705. HLAB2702, on the other hand, has been discovered to have a reduced rate of In comparison to HLAB2706, proper folding processes were used. and HLA-B2709, which aren't usually thought to be linked with AS. (72) HLAB27 folds slower than other HLA alleles for a variety of reasons, including cysteine residue C67, and without appropriate folding, these faulty HLA-B27 proteins accumulate in the ER. (70) HLA-B27 proteins with incorrect folding accumulate in the endoplasmic reticulum (ER) and trigger autophagy and the The interleukin (IL)-23/IL-17 route is an interleukin (IL)-23/IL-17 pathway. (69) Furthermore, the misfolded ER stress can be caused by chemicals that interfere with ER function, prompting the pro-inflammatory endoplasmic reticulum unfolded protein response (ERUPR), which then activates the ER. the interleukin-23/interleukin-17 (IL-23/IL-17) pathway.(69)(73) However, there are questions over whether the HLA-B27-activated ERUPR is present in AS patients. The increased synthesis of interleukin 23 (IL23) without a significant rise in In AS, ERUPR is induced in macrophages.(74) The ailment Polymorphisms in the ERAP1 or HLAB27 loci might be associated. AS, (75) ER stress levels did not alter, despite the fact that Other investigations done later on found that the findings were still debatable. 14 One theory is that HLA-B27 misfolding causes autophagy. Instead of ERUPR, it activates the IL-23/IL-17 pathway.(76) More investigation is required.

Non-HLA-B27 MHC alleles

Other non-HLA-B27 MHC alleles, including numerous MHC-I or II locations, have been linked to the etiology of AS, in addition to the generally established HLA-B27 genetics. These HLA-B40, HLA-B60, HLA-A, HLA-DRB1, HLADQA1, HLA-DPB1, and other genes have a role in the development of AS. TCRs and KIRs expressed on NK cells interact with each other, and Antigen presentation is carried out by some lymphocytes, and additional types of inflammatory reactions (77)HLA-G, for example, was discovered to have A totally folded 2m related form has been shown to create homodimers in cell organelle endosomes. Non HLA-B27 genes may work independently or in concert with HLA-B27 through linkage disequilibrium. Furthermore, the HLA-A0201 tag SNP Independent of HLA-B27, rs2394250 has been linked to AS. for AS patients who are HLA-B27-positive or HLA-B27-negative. (78) The The processes through which certain MHC genes that are not HLA-B27 impact AS are mainly undiscovered. More research into the non-HLA-B27 variants is needed. The MHC allele may provide insight into the pathophysiology of SpA and other diseases & additional illnesses that are connected.

Non-MHC genetics

MHC genes have been the focus of research on the pathophysiology of AS over the past four decades. However, the development of GWAS methodologies and the discovery of a large number of genes has resulted in the identification of a large number of genes.

The relevance of non-MHC genes was highlighted through genetic variations. Despite the fact that HLA-B27 contributes just 20% of the total, HLA-B27 is a large contribution, accounting for 7% of heritable risk. is derived from non-MHC variations (47)(79)(80) As a result, non-MHC In the pathophysiology of AS, heredity plays a role. Furthermore, various routes or processes have been implicated In recent years, AS procedures have become more complex.

ERAP1 and ERAP2

Three previously identified amino peptidases, ERAP1 (coding for endoplasmic reticulum amino peptidase 1 (ERAP1)), ERAP2 (coding for endoplasmic reticulum amino peptidase 2 (ERAP2)), and ERAP3 (coding for endoplasmic reticulum amino peptidase 2 (ERAP2)), were identified as genetically related to AS vulnerability. NPEPPS (coding for puromycin-sensitive amino peptidase (PSA)) and ERAP2 (coding for ERAP2).(78)(81) According to recent studies, gene-to-gene communication is possible. interactions between HLA-B27 and ERAP1 and the resulting abnormalities The development of AS is thought to be influenced by peptide presentation. (78)(82) Protective factors were discovered in a case-control study. ERAP1 function was shown to be hampered by genetic variations. MHC-I expression on the cell surface was reduced by ERAP2 and ERAP2. (78) Variations in ERAP1 and ERAP2 may also slow down HLA-B27. folding affects the quantity of relevant peptide that can be accessed, As a result, ER stress and AS development are increased.(77)

Both ERAP1 and ERAP2, which are found on chromosome 5q15, help to trim peptides in the ER to nine amino acids in preparation for antigen presentation by HLA-I molecules like HLA-B27.(83) Furthermore, ERAP1 can still cut antigen processing and presentation. IL-1R2, for example, is one of numerous cytokine receptors on the cell surface. TNFR1 and IL-6R, lowering their capacity to convey signals to other cells. The latter has an impact on inflammatory processes as well. (84) These In the development of AS and other diseases, two genes are implicated. illnesses. HLAB27 and HLA-C are said to be linked to ERAP1. AS,(83)is B40positive, whereas ERAP2 is linked to HLAB27+ and HLAB27-. B27 AS.(85) ERAP1 is also engaged in juvenile development. idiopathic arthritis, psoriasis, and Behçet's disease, while ERAP2 idiopathic arthritis, psoriasis, and Behçet's disease associated with Crohn's disease, psoriasis, and birdshot chorioretinopathy, with unknown mechanisms,(79)

Immune cells and innate cytokines

AS is a kind of seronegative spondyloarthritis that is characterised by persistent inflammation including DCs, macrophages, natural killer cells, and adaptive immune cells. (86) Innate cytokines are produced by these immune cells and play an important function in the immune system. Human DCs are found in CD1cpositive (conventional DC1) and CD141-positive (conventional DC2) lymphatic and nonlymphatic organs are separated. (87)(88) DC2) subsets Plasmacytoid DCs are a different kind of DC. Dendritic cells (pDCs) resemble plasma cells in look and function. may generate dendritic cell antigen 2 (CD56+, HLA-DR)(BDCA-2), Toll-like receptor 7 (TLR7), CD123, and TLR9 are all toll-like receptors that may be found in the body. The absence of a plasma membrane distinguishes these cells from monocytes and traditional DCs. Expression of CD14 and CD11c.(89)(90) Aside from that, they serve a purpose. These cells participate

in both inborn and adaptive immunological mechanisms. contribute in humoral immunity mediated by B cells.(89)

The number of macrophages in an AS patient's blood is proportional to the severity of the condition. (91)(92) In the bone marrow, large numbers of CD68-positive macrophages or osteoclasts were seen. AS sufferers' sacroiliac joint lesions Previous study has found that CD163+ macrophages have a critical function in inflammatory tissues, according to new research. SpA patients' bodily parts (93) Furthermore, the number of In SpA patients, macrophages were decreased following medication treatment.(94) HLA-B27/human 2m transgenic rats were used in a prior investigation. HLA-B27+ macrophages generated IL-23-based cytokines, according to research. inflammatory variables that played a role in the development of the disease enthesopathy.(95) The expression of IL-23 was measured in the clinic. In AS patients, synovium tissues and serum levels are much higher. when compared to healthy controls.(96)

Complications

Spinal fracture is the most dangerous consequence associated with AS. Minor stress to the stiff, fragile spinal column might result in serious consequences. The cervical spine is the most vulnerable area, with fractures resulting in quadriplegia. Prostatitis is very common in males who have AS. Aortic It is possible to develop insufficiency and cardiac conduction abnormalities. among people who have had a long-term illness Cauda equina amyloidosis Syndrome and lung fibrosis are uncommon side effects.

Socioeconomic impact

Three dimensions must be identified when assessing the socioeconomic repercussions of an illness. To begin with, there is the (in-)ability to continue working, whether paid or unpaid. In monetary terms, these charges are known as productivity costs. Second, there is the Use of health resources relates to sickness, which can be regarded as direct expenses Finally, the disease's influence on the quality of life. life and psychological well-being that can't be quantified Intangible costs are costs that cannot be measured in monetary terms. Because AS commonly begins at a young age, it can last a lifetime. The disease's socioeconomic impact can be significant. patient as well as for the sake of society Until now, the socioeconomic situation has been rather stable. The implications of AS have gotten little attention. When It's difficult to evaluate published reports on this issue. Data from research conducted in different nations may be compared. Social security and healthcare systems differ, which puts a limit on what may be done. efforts to make generalisations and parallels concerning socioeconomic data.

Treatment for AS

Pharmacological effect

Treatment for AS attempts to enhance and preserve spinal flexibility and normal posture, as well as relieve symptoms, minimise functional limitations, and reduce consequences. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the cornerstones of pharmacological therapy. TNF-inhibitors with non steroidal anti-inflammatory drugs (NSAIDs) (TNFi). There are many other therapies available. Non-TNFi biologics (secukinumab), methotrexate, and sulfasalazine are examples of non-TNFi biologics. Furthermore, the oral JAK inhibitors tofacitinib and nilotinib Filgotinib has shown promise in clinical studies and might be available shortly. AS.(97)(98) has been authorised. There are a number of guidelines for managing AS. Expert committees in France,(99) Spain,(100) and the United Kingdom have released statements. Tukey,(101) Canada, (102)(103) the United Kingdom, (104)the United States(105), and the United Nations

Europe,(106) all of which are based on thorough literature assessments. As There is great agreement among them, as seen in strategies. Regardless matter whether the condition is severe or mild, Whether active or stable, physical therapy,(107) exercise, and refraining from alcohol and Smoking(108) is widely recommended.

For individuals with active AS, NSAIDs, particularly selective inhibitors of cyclooxygenase 2, are the first-line therapy. Laboratory (CRP/ESR), clinical, and other factors are used to determine whether or not a patient has active disease. Findings from MRI (magnetic resonance imaging). (109) Continuous NSAID medication is more effective than on-demand treatment. has demonstrated no clinical benefits,(110) whereas hypertension has. Individuals who are going through a difficult time are more likely to suffer from anxiety and sadness. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) is ongoing. Continuous usage, on the other hand, should be avoided. If symptom recurrence occurs after discontinuing or lowering the dose, see your doctor. the NSAID drug's dosage (111)(112) An increase in the number of people with active AS is associated with a decrease in the number of people At least two types of NSAIDs should be included in an adequate experiment. given for a minimum of 2 weeks and a maximum of 4 weeks Unless contraindicated, use the lowest dose that is tolerable.(113) Despite this, the NSAIDs should be used at the 'lowest effective dose', according to the guidelines. The National Institute for Health and Care Excellence (NICE) is a non-profit organisation dedicated to improving health (NICE) guidelines.(104) In terms of preferred NSAIDs, none are advised efficacy. In terms of desired effectiveness, no NSAID is advised. Treatment with NSAIDs should be based on the patient's NSAID usage history, comorbidities, and risk factors. negative consequences (105) A decrease in the use of NSAIDs is a good response. in the treatment of inflammatory back pain and the development of functional abilities An Active is defined as a lack of response to NSAID treatment. Not withstanding the use of at least two distinct nonsteroidal anti-inflammatory drugs (NSAIDs) at the highest anti-inflammatory dose and for the longest time (at least) Each will take two weeks). Intolerance or unfavourable consequences are also possible. involved. Analgesics, particularly opioid-like medications, may be used. when NSAID therapy fails or is contraindicated (101)(106)

TNF inhibitors are recommended for individuals with high disease activity, even if they are taking NSAIDs. (105) Disease activity indicators that stay above particular cut-offs indicate an inadequate response to TNFi. Over time, (BASDAI 4 or AS Disease Activity Score (ASDAS) 2.1) The ASDAS accurately depicts the inflammatory state. It is recommended to use BASDAI and its cut-offs. Biological agents must be avoided. employed in accordance with their indications and contraindications, as well as comorbidities of the patient For desired, no TNFi is indicated. efficacy. Furthermore, infliximab or adalimumab therapy is effective. For people with IBD or inflammatory bowel disease, it is preferable over etanercept therapy. Recurrent iritis is a common occurrence. (114)(115) indicators of a favourable reaction to TNFis are a disease with a brief duration and a patient age of less than 40 years. There is no enthesitis, HLA-B27 positive, decent functional status, and a high CRP level.(116) Male sex was also found to be a reliable predictor of TNF response in a Swiss investigation. TNFis are contraindicated in the presence of an active infection, TB, severe heart failure, lupus, multiple sclerosis, and other diseases. cancer. In individuals with active AS and contraindications to treatment Sulfasalazine or pamidronate are preferred over nonTNFi biologics like abatacept and tocilizumab for TNFis. (105)As soon as AS When the first TNFi fails to work, the patient is given a second TNFi. It is suggested that you use a biologic. IL-17 can be produced by a variety of biologics. IL-17i inhibitor or a different TNFi.(117) The procedure should be followed. if there is no substantial improvement after applying for It's been three months. If there is no clinical remission after a 6-month trial, If the severity of the condition decreases, the therapy must be altered. After Following the failure of the first TNFi, a second TNFi with a lower dose is administered. Effectiveness may also be efficacy.(117) However, before making the transition, It is necessary to receive therapy. Initial failure might be attributable to an inaccurate diagnosis

rather than drug resistance, given the conditions of a primary lack of effectiveness. Moreover, the symptoms and indications might be caused by either a separate or concurrent ailment. In some cases, biologics may fail. Patients with AS with a spinal fracture or degenerative disc disease of the discs. In patients who have been in remission for a long time, the tapering of Treatment with TNFi or IL-17i is an option. (118) The duration of At least 6 months of remission is required. Tapering can be done in a number of ways. remained at zero (withdrawal). However, just a small amount of tapering is required. It is advisable that you take things carefully and give yourself plenty of time for remission. before moving on to the next stage of the tapering procedure

Enthesopathy and arthritis appear to be treatable with local glucocorticoid injections. Injections of glucocorticoids into the affected peripheral joints, sacroiliac joints, or entheses might help. Symptoms will be relieved right away. Previous research has revealed that this is partially due to an increased risk of osteoporosis, long-term therapy for hyperlipidemia and insulin resistance. The use of systemic glucocorticoids is generally discouraged. A recent study found that According to a research, people with AS were able to get alleviation from their symptoms and symptoms. Symptoms following a short-term course of high-doses of 50 mg glucocorticoids each day(119) When it comes to persons with peripheral arthritis, Conventional synthetic disease-modifying drugs are a comorbidity. Methotrexate, leflunomide, and sulfasalazine are examples of antirheumatic medicines (csDMARDs) that should be examined, but not in people who are allergic to them. with axSpA enthesitis or isolated axSpA Treatment with methotrexate has helped 172 people. In individuals with AS who do not have peripheral neuropathy, it has not been proved to be beneficial. arthritis, regardless of whether or not a TNFi was used.

It is suggested that individuals with stable AS use NSAIDs on a need-to-basis. It is recommended to continue therapy with TNFi alone rather than combining it with an NSAID or DMARD. (120)The long-term use of NSAIDs or DMARDs is risky. Having higher gastrointestinal risks as a side effect, Toxicity in the cardiovascular, renal, and haematological systems.(121)

Surgical treatment

Untreated AS can lead to spinal deformity, with thoracolumbar kyphosis affecting more than 30% of AS patients. (122) In surgical treatments, corrective osteotomy and stabilisation are extremely prevalent. and are advised in some circumstances, such as adulthood(105). people with advanced hip arthritis or significant kyphosis This The surgery has a 4% perioperative mortality rate and a permanent outcome. A 5-percentage-point risk of neurologic sequelae. (119)This operation has been proved to be effective. aid in the prevention of natural progressive processes deformities, lowering muscle fatigue-related pain, and enhancing disability, re-establishing global equilibrium and a horizontal axis of vision, as well as bettering respiratory and digestive functions (124-131)

Closing- vs. opening wedge osteotomy (CWO/OWO) treatments are fundamentally distinct osteotomy methods for the treatment of kyphotic deformity. (131) Smith-Petersen et al. initially developed OWO in 1945, and it has since become widely used. Several surgeons have tinkered with it. (132,133) In order to rectify the This procedure induces a kyphotic malformation of the lumbar spine. manual extension is required because to a gap in the laminae and spinous processes. The lumbar spine is the lowest part of the spine. Because of this, the complication rate is relatively high. the anterior column's elongation and the strong lordotic angle happening during this treatment, which might result in significant vascular and neurological complications (134,135) neurological injuries Wilson et al. came up with a solution to this problem. In 1949, the poly-segmental wedge osteotomy (PWO) was first introduced. Zielke modified the design in the 1980s. There was a correction made. Multiple CWOs in the posterior lumbar spine were used to achieve this.

provide a more aesthetically pleasing opening of the anterior disc spaces spanning with tempered posterior shortening. In contrast to the previous treatment, Zielke and his colleagues proposed PWO with internal fixation utilising Harrington rods, laminar hooks, and Transpedicular screws were used afterwards. Nonetheless, when it comes to instruments, Implant failure has been reported in more than 40% of patients. The intervertebral disc has restricted movement and has a substantial influence. (136) As a result, the postoperative satisfaction rates were substantially below the national average. rates that are predicted (136-138)

Scudese and Calabro originally introduced monosegmental CWO in 1963, and Ziwjan in 1982 and Thomasen in 1985 further improved it. (139-141) The posterior is exposed during this surgery. one vertebra's elements in combination with the posterior To accomplish correction, a wedge of the vertebral body is removed. The lumbar spine is extended in a passive manner. Internal PWO is similar to PWO. In order to improve instant stability, fixation is also required. In this case, Correction is made using this procedure. The postoperative period, on the other hand, The satisfaction and complication rates of CWO appear to be higher than the national average. (141,142) Those of OWO or PWO

A uncommon consequence of long-term AS is cauda equina syndrome (CES). Without adequate therapy, neurological problems develop slowly and have a bad prognosis. Chronic arachnoiditis and dural fibrosis may cause CES in people with AS. CSF resorption is reduced when the dural sac is present. dilatation and the development of diverticula (143) Leaving these patients unattended It is not appropriate to leave a patient untreated or to treat them solely with steroids. Surgical lumboperitoneal shunting or surgery to address dural ectasia Laminectomy can help with neurological problems or perhaps stop them from getting worse. degeneration of the nervous system (144)

Rheumatologists frequently detect hip abnormalities in AS patients, which affects one-fourth to one-third of the population. (145) The ACR has proposed, based on data, For people with arthritis, arthroplasty is the best therapy choice. Those with advanced hip arthritis and acute hip discomfort who would often Otherwise, mobility and independence will deteriorate with time.(105)

THA has been the subject of several research, despite the fact that it may be a challenging treatment for individuals with AS. According to current findings, THA can produce good outcomes, significantly enhancing hip joint function. Without causing substantial difficulties, function and pain relief can be achieved. (146-150)Nonetheless, observational studies and case series are the sole sources of evidence regarding THA's effectiveness in AS patients. There are still debates over surgery time, implant selection, and perioperative care. Heterotopic ossification (HO) prevention and treatment options Concomitant severe hip and spinal deformity is especially difficult to treat, and no consensus exists on which deformity should be repaired. first.(146,151–155) Some people believe that a spinal fusion should be done before THA. To lessen the risk of hip fracture, an osteotomy should be done. dislocation.(146,152–154)

Drug and surgical therapy are the mainstays of AS treatment. NSAIDs and TNF-alpha inhibitors are the most often prescribed medications for AS in clinic. Furthermore, interleukin receptor blockers and several anti-inflammatory drugs Inhibitors of new bone growth have seen a rise in popularity. IL-6, for example, has attracted a lot of attention and will be the subject of future research. Sarilumab, a receptor inhibitor, and inhibitors of the Wnt signalling pathway More severe abnormalities may occur if AS is not successfully treated. There is a necessity for surgical therapy when these symptoms arise. In the case of severe spinal stenosis Spinal surgery is necessary for abnormalities. In the case of sacroiliac joint lesions, A complete hip replacement is required. AS has always been treated in a unique way. the world's most important research centre Currently, the investigation is ongoing. The choice of surgical therapy for AS is a hotspot of surgical

treatment. The surgical route, perioperative care, and the prevention and treatment of infections are all covered. Complications, including HO, are treated. With scientific and technological advancements, With advancements in technology, early detection and successful treatment of AS will be achievable. The economical burden of AS will be greatly lessened, and the suffering of sufferers will be greatly reduced.

Conclusion

Ankylosing spondylitis is a painful and debilitating condition that has significant socioeconomic consequences. The annual mean total (direct and productivity) costs of AS in 2002 were US\$6,720 per person per patient in the United States and Euro 9 462 per patient in Europe (156)There is currently no effective disease-modifying medication, owing to the fact that Pathogenesis is unknown. The focus of this review is on the aetiology. Asthma aetiology and treatment progress The origins of Ankylosing spondylitis is thought to be linked to a person's genetic origin. Immune function, pathogenic infection, and endocrine disorders are all factors to consider. as well as other aspects HLA-B27 is a critical gene for human development. The non-HLA-B27 gene is also linked to ankylosing spondylitis. It plays an important role in the pathogenesis of the disease. Differences in genetics diverse races, especially those of East Asian and Caucasian ancestry, GWASs have been discovered and may shed light on treatment approaches Ankylosing spondylitis is linked to autoimmune illnesses and microbial infections, implying that they have a shared immunological and genetic base. Hormone imbalances and vitamin D deficiency are also possible reasons.

AS has a complicated pathogenesis. According to recent research, it could be the result of a number of complex mechanisms. Various ideas, such as the false positive hypothesis, have been proposed in the aetiology of AS. Attempt to understand the role of HLA-B27 through folding hypothesis. Ankylosing spondylitis may be influenced by non-HLA-B27 genes. Immune function and gene interaction have a role in spondylitis. Overexpression of ERAP1 and ERAP2 is also thought to be a problem. AS has an essential pathogenesis. There are several factors and associated genes in This avenue is continually being explored. Furthermore, related The dysfunction of the IL-23/IL-17 axis and its consequences have been the subject of investigation. Activation and differentiation of lymphocytes are aberrant. Most According to reports, immune cells and cytokines are involved in the process. Asthma pathogenesis The IL-23/IL-17 pathway, in particular, is important. It plays a critical function in the progression of the illness. Currently, the immunological T cells are thought to have a major role in the pathophysiology of AS. B cells, on the other hand are a little bit involved. Some research has been done on the pathophysiology of AS mediated by B lymphocytes, and future research in this area may be expanded. Alternatively, scientists might continue to look at the relationship between cytokines and the immune system to anticipate the appearance, growth, and progression of cells and illnesses the severity of the condition Although the cause of ankylosing spondylitis is unknown, Although the cause of spondylitis is unknown, present scientific findings may have an impact. clinical practice has a certain guiding significance.

Drug and surgical therapy are the mainstays of AS treatment. NSAIDs and TNF-alpha inhibitors are the most often prescribed medications for AS in clinic. Furthermore, interleukin receptor blockers and several anti-inflammatory drugs Inhibitors of new bone growth have seen a rise in popularity. IL-6, for example, has attracted a lot of attention and will be the subject of future research. Sarilumab, a receptor inhibitor, and inhibitors of the Wnt signalling pathway More severe abnormalities may occur if AS is not successfully treated. There is a necessity for surgical therapy when these symptoms arise. In the case of severe spinal stenosis Spinal surgery is necessary for abnormalities. In the case of sacroiliac joint lesions, A complete hip replacement is required. AS has always been treated in a unique way. the world's most important research centre Currently, the investigation is ongoing. The choice of surgical therapy for AS is a hotspot of surgical

treatment. The surgical route, perioperative care, and the prevention and treatment of infections are all covered. Complications, including HO, are treated. With scientific and technological advancements, With advancements in technology, early detection and successful treatment of AS will be achievable.

References

- (1) Farrouq m, Philip H. psoriatic arthritis: A review. *EMJ Rheumatol* 2016;3:114-7
- (2) Wang, C.-R. et al. Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study. *Sci. Rep.* 7, 13165–13165 (2017).
- (3) Lindström, U., Olofsson, T., Wedrén, S., Qirjazo, I. & Askling, J. Impact of extraarticular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study. *RMD open* 4, e000762–e000762 (2018).
- (4) Moltó, A. & Nikiphorou, E. Comorbidities in spondyloarthritis. *Front. Med.* 5, 62–62 (2018).
- (5) Reveille, J. D. & Weisman, M. H. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. *Am. J. Med. Sci.* 345, 431–436 (2013).
- (6) Reveille, J. D., Hirsch, R., Dillon, C. F., Carroll, M. D. & Weisman, M. H. The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. *Arthritis Rheum.* 64, 1407–1411 (2012).
- (7) de Winter, J. J., van Mens, L. J., van der Heijde, D., Landewe, R. & Baeten, D. L. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. *Arthritis Res. Ther.* 18, 196 (2016).
- (8) Brown, M. A., Laval, S. H., Brophy, S. & Calin, A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. *Ann. Rheum. Dis.* 59, 883–886 (2000).
- (9) van Tubergen, A. & Weber, U. Diagnosis and classification in spondyloarthritis: identifying a chameleon. *Nat. Rev. Rheumatol.* 8, 253–261 (2012).
- (10) Taugrog, J. D., Chhabra, A. & Colbert, R. A. Ankylosing spondylitis and axial spondyloarthritis. *N. Engl. J. Med.* 375, 1303 (2016).
- (11) J sieper, J braun, M Rudwaleit, A BOONEN, A ZINK Ankylosing spondylitis: an overview(Extended report)
- (12) Patient. Dr. Nicklmm. Ankylosing spondylitis. Available from:<http://www.patient.info/doctor/ankylosing-spondylitis-pro>.
- (13) Fellman J. Correct and incorrect paths in the history of ankylosing spondylitis. *Schweiz Rundsch Med Prax* 1991;80:576–9.
- (14) Ruffer MA. Studies of the paleopathophysiology of Egypt. Chicago: University of Chicago Press; 1921.
- (15) Colombo MR. De Re Anatomica Venice, 1559.
- (16) Connor B. Lettre écrite à Monsieur le chevalier Guillaume de Waldegrave, premier médecin de sa Majeste Britannique. Paris, 1693:17
- (17) Connor B. Dissertationes medico-physicae. Sheldonian Theatre, Oxford, 1695:206. (NY Acad Med and Royal Soc.)
- (18) Connor B. An extract from a letter to Sir Charles Walgrave, published in French at Paris: Giving an account of an extraordinary humane skeleton, whose vertebrae of the back, the ribs and several bones down to the os sacrum, were firmly united into one solid bone, without jointing or cartilage. *Philos Trans* 1695;19:21–7.
- (19) Arnett FC. Ankylosing spondylitis 1992: from Connor to transgenes. *J Ir Coll Physicians Surg* 1993;22:207–11.
- (20) Strümpell A. Bemerkungen über chronisch-ankylosierende Entzündung der Wirbelsoule und der Hüftgelenks. *Deutsch Nervenheilk* 1897;11:338–42.
- (21) Forestier J. Gilbert Scott memorial oration. Ankylosing spondylitis at the beginning of the century. *Rheumatism (Journal of the Charterhouse Rheumatism Clinic)* 1964;20:28–53.
- (22) Forestier J, Jacqueline F, Rolesquerol J, eds. Ankylosing spondylitis: clinical considerations, roentgenology, pathologic anatomy, treatment. Springfield (IL): Charles C Thomas; 1956. (Translated by AU Desjardins.
- (23) Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behçet's syndrome. *Medicine (Baltimore)* 1974;53:343–64.
- (24) 9 Bauer W, Engleman EP. A syndrome of unknown etiology characterized by urethritis, conjunctivitis and arthritis [so-called Reiter's disease]. *Trans Assoc Am Physicians* 1942;57:307–13.
- (25) Paronen I. Reiter's disease. A study of 344 cases observed in Finland. *Acta Med Scand* 1948;131(suppl):1–114.
- (26) Ahvonen P, Sievers K, Aho K. Arthritis associated with Yersinia enterocolitica infection. *Acta Rheumatol Scand* 1969;15:232–53.
- (27) Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. *N Engl J Med* 1973;288:704–6
- (28) Brewerton DA, Caffrey M, Nicholls A, Walters D, Oates JK, James DC. Reiter's disease and HL-A 27. *Lancet* 1973;ii:996–8.
- (29) Ebringer, RW, Cawdell DR, Cowling P, Ebringer A. Sequential studies in ankylosing spondylitis. Association of Klebsiella pneumoniae with active disease. *Ann Rheum Dis* 1978;37:146–51.
- (30) Maki-Ikola O, Lehtinen K, Granfors K, Vainionpaa R, Toivanen P. Bacterial antibodies in ankylosing spondylitis. *Clin Exp Immunol* 1991;84:472–5.
- (31) Mielants H, Veys EM, Joos R, Noens L, Cuvelier C, De Vos M. HLA antigens in seronegative spondylarthropathies. Reactive arthritis and arthritis in ankylosing spondylitis: relation to gut inflammation. *J Rheumatol* 1987;14:466–71.
- (32) Brown, M. A. et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. *Arthritis Rheum.* 40, 1823–1828 (1997).
- (33) Reveille, J. D. The genetic basis of ankylosing spondylitis. *Curr. Opin. Rheumatol.* 18, 332–341 (2006).
- (34) Brewerton, D. A. et al. Ankylosing spondylitis and HL-A 27. *Lancet* 1, 904–907 (1973).
- (35) Reveille, J. D. The genetic basis of spondyloarthritis. *Ann. Rheum. Dis.* 70, i44–i50 (2011).
- (36) Brown, M. A. Genetics of ankylosing spondylitis. *Curr. Opin. Rheumatol.* 22, 126–132 (2010).
- (37) Taugrog, J. D. The mystery of HLA-B27: if it isn't one thing, it's another. *Arthritis Rheum.* 56, 2478–2481 (2007).

- (38) Feldtkeller, E., Khan, M. A., van der Heijde, D., van der Linden, S. & Braun, J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. *Rheumatol. Int.* 23, 61–66 (2003).
- (39) Khan, M. A. Polymorphism of HLA-B27: 105 subtypes currently known. *Curr. Rheumatol. Rep.* 15, 362 (2013).
- (40) Uchanska-Ziegler, B., Ziegler, A. & Schmieder, P. Structural and dynamic features of HLA-B27 subtypes. *Curr. Opin. Rheumatol.* 25, 411–418 (2013).
- (41) Sorrentino, R., Bockmann, R. A. & Fiorillo, M. T. HLA-B27 and antigen presentation: at the crossroads between immune defense and autoimmunity. *Mol. Immunol.* 57, 22–27 (2014).
- (42) Wucherpfennig, K. W. Presentation of a self-peptide in two distinct conformations by a disease-associated HLA-B27 subtype. *J. Exp. Med.* 199, 151–154 (2004).
- (43) D'Amato, M. et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. *Eur. J. Immunol.* 25, 3199–3201 (1995).
- (44) Koh, W. H. & Boey, M. L. Ankylosing spondylitis in Singapore: a study of 150 patients and a local update. *Ann. Acad. Med. Singap.* 27, 3–6 (1998).
- (45) Tran, T. M. et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. *Arthritis Rheum.* 54, 1317–1327 (2006).
- (46) Weinreich, S. S., HoebeHewryk, B., vanderHorst, A. R., Boog, C. J. P. & Ivanyi, P. The role of MHC class I heterodimer expression in mouse ankylosing enthesopathy. *Immunogenetics* 46, 35–40 (1997).
- (47) Breban, M., Said-Nahal, R., Hugot, J. P. & Miceli-Richard, C. Familial and genetic aspects of spondyloarthropathy. *Rheum. Dis. Clin. North Am.* 29, 575–594 (2003).
- (48) Wei, J. C., Tsai, W. C., Lin, H. S., Tsai, C. Y. & Chou, C. T. HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients. *Rheumatology* 43, 839–842 (2004).
- (49) Wei, J. C. et al. Interaction between HLA-B60 and HLA-B27 as a better predictor of ankylosing spondylitis in a Taiwanese population. *PLoS ONE* 10, e0137189 (2015).
- (50) Khan, M. A., Kushner, I. & Braun, W. E. A subgroup of ankylosing spondylitis associated with HLA-B7 in American blacks. *Arthritis Rheum.* 21, 528–530 (1978).
- (51) Khan, M. A., Kushner, I. & Braun, W. E. B27-negative HLA-BW16 in ankylosing spondylitis. *Lancet* 1, 1370–1371 (1978).
- (52) Wagoner, P., Zeidler, H., Eckert, G. & Deicher, H. Increased frequency of HLABw62 and Bw35 CREG antigens in HLA-B27 negative ankylosing spondylitis. *Z. Rheumatol.* 43, 253–257 (1984).
- (53) Consortium, W. T. C. C. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. *Nat. Genet.* 39, 1329–1337 (2007).
- (54) Rudwaleit, M. et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. *Ann. Rheum. Dis.* 60, 36–42 (2001).
- (55) Sieper, J., Braun, J. & Kingsley, G. H. Report on the fourth international workshop on reactive arthritis. *Arthritis Rheum.* 43, 720–734 (2000).
- (56) Taurog, J. D. et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. *J. Exp. Med.* 180, 2359–2364 (1994).
- (57) Rath, H. C. et al. Normal luminal bacteria, especially *Bacteroides* species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. *J. Clin. Invest* 98, 945–953 (1996).
- (58) Costello, M. E. et al. Brief report: intestinal dysbiosis in ankylosing spondylitis. *Arthritis Rheuma.* 67, 686–691 (2015).
- (59) Gomez-Simmonds, A. & Uhlemann, A. C. Clinical implications of genomic adaptation and evolution of carbapenem-resistant *Klebsiella pneumoniae*. *J. Infect. Dis.* 215, S18–S27 (2017).
- (60) Zhang, L. et al. The association of HLA-B27 and *Klebsiella pneumoniae* in ankylosing spondylitis: a systematic review. *Micro. Pathog.* 117, 49–54 (2018).
- (61) Sieper, J. & Braun, J. Pathogenesis of spondylarthropathies. *Arthritis Rheum.* 38, 1547–1554 (1995).
- (62) Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. *J Rheumatol* 2001;28:2667–73.
- (63) Madden, D. R. The three-dimensional structure of peptide-MHC complexes. *Annu. Rev. Immunol.* 13, 587–622 (1995).
- (64) Toh, H. et al. Changes at the floor of the peptide-binding groove induce a strong preference for Proline at position 3 of the bound peptide: Molecular dynamics simulations of HLA-A*0217. *Biopolymers* 54, 318–327 (2000).
- (65) Nguyen, T. T. et al. Structural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1. *Nat. Struct. Mol. Biol.* 18, 604–613 (2011).
- (66) Yewdell, J. W. DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. *Trends Immunol.* 32, 548–558 (2011).
- (67) Alvarez-Navarro, C. & de Castro, J. A. L. ERAP1 structure, function and pathogenetic role in ankylosing spondylitis and other MHC-associated diseases. *Mol. Immunol.* 57, 12–21 (2014).
- (68) Schittenhelm, R. B., Te, L. K. S., Wilmann, P. G., Dudek, N. L. & Purcell, A. W. Revisiting the arthritogenic peptide theory: Quantitative not qualitative changes in the peptide repertoire of HLA-B27 allotypes. *Arthritis Rheuma.* 67, 702–713 (2015).
- (69) Colbert, R. A., DeLay, M. L., Layh-Schmitt, G. & Sowders, D. P. HLA-B27 misfolding and spondyloarthropathies. *Adv. Exp. Med Biol.* 649, 217–234 (2009).
- (70) Colbert, R. A., Tran, T. M. & Layh-Schmitt, G. HLA-B27 misfolding and ankylosing spondylitis. *Mol. Immunol.* 57, 44–51 (2014).
- (71) Chen, B. et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (review). *Mol. Med. Rep.* 15, 1943–1951 (2017).
- (72) Antoniou, A. N., Ford, S., Taurog, J. D., Butcher, G. W. & Powis, S. J. Formation of HLA-B27 homodimers and their relationship to assembly kinetics. *J. Biol. Chem.* 279, 8895–8902 (2004).
- (73) Turner, M. J. et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. *J. Immunol.* 175, 2438–2448 (2005).
- (74) Zeng, L., Lindstrom, M. J. & Smith, J. A. Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. *Arthritis Rheum.* 63, 3807–3817 (2011).

- (75) Kenna, T. J. et al. Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis. *Genes Immun.* 16, 35–42 (2015).
- (76) Colbert, R. A., Delay, M. L., Layh-Schmitt, G. & Sowders, D. P. HLA-B27 misfolding and spondyloarthropathies. *Prion.* 3, 15–26 (2009).
- (77) Reveille, J. D. An update on the contribution of the MHC to AS susceptibility. *Clin. Rheuma.* 33, 749–757 (2014).
- (78) International Genetics of Ankylosing Spondylitis Consortium. et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat. Genet.* 45, 730–738 (2013).
- (79) Brown, M. A., Kenna, T. & Wordsworth, B. P. Genetics of ankylosing spondylitis—insights into pathogenesis. *Nat. Rev. Rheumatol.* 12, 81–91 (2016).
- (80) Ellinghaus, D. et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nat. Genet.* 48, 510–518 (2016).
- (81) Wellcome Trust Case Control Consortium. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. *Nat. Genet.* 39, 1329–1337 (2007).
- (82) Graham, D. S. C. et al. Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. *Hum. Mol. Genet* 16, 579–591 (2007).
- (83) Kanaseki, T., Blanchard, N., Hammer, G. E., Gonzalez, F. & Shastri, N. ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. *Immunity* 25, 795–806 (2006).
- (84) Cui, X. et al. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. *J. Clin. Invest* 110, 515–526 (2002).
- (85) Robinson, P. C. et al. ERAP2 is associated with ankylosing spondylitis in HLA-B27- positive and HLA-B27-negative patients. *Ann. Rheum. Dis.* 74, 1627–1629 (2015).
- (86) Rezaïmanesh, A. et al. Immune cells involved in the pathogenesis of ankylosing spondylitis. *Biomed. Pharmacother.* 100, 198–204 (2018).
- (87) O’Keeffe, M., Mok, W. H. & Radford, K. J. Human dendritic cell subsets and function in health and disease. *Cell. Mol. Life Sci.* 72, 4309–4325 (2015).
- (88) Guilliams, M. et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. *Nat. Rev. Immunol.* 14, 571–578 (2014).
- (89) McKenna, K., Beignon, A. S. & Bhardwaj, N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. *J. Virol.* 79, 17–27 (2005).
- (90) Zang, M., Chen, K., Qu, C. & Brinckjensen, N. S. Monocyte-derived dendritic cells: targets as potent antigen-presenting cells for the design of vaccines against infectious diseases. *Int. J. Infect. Dis.* 19, 1–5 (2014).
- (91) Talpin, A. et al. Monocyte-derived dendritic cells from HLA-B27+ axial spondyloarthritis (SpA) patients display altered functional capacity and deregulated gene expression. *Arthritis Res. Ther.* 16, 417 (2014).
- (92) Kruihof, E. et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. *Arthritis Res. Ther.* 7, R569 (2005).
- (93) Mulherin, D., Fitzgerald, O. & Bresnihan, B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. *Arthritis Rheum.* 39, 115–124 (2010).
- (94) Barry, B. et al. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. *J. Rheuma.* 36, 1800–1802 (2009).
- (95) Rezaïmanesh, A. et al. Ankylosing spondylitis M-CSF-derived macrophages are undergoing unfolded protein response (UPR) and express higher levels of interleukin-23. *Mod. Rheuma.* 27, 862–867 (2017).
- (96) Jethwa, H. & Bowness, P. The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment. *Clin. Exp. Immunol.* 183, 30–36 (2016).
- (97) van der Heijde, D. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. *Ann. Rheum. Dis.* 76, 1340–1347 (2017).
- (98) van der Heijde, D. et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. *Lancet (Lond., Engl.)* 392, 2378–2387 (2018).

- (99) Wendling, D. et al. 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. *Jt. Bone Spine* 85, 275–284 (2018)
- (100) Torre-Alonso, J. C. et al. Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. *Rheumatol. Int.* 37, 1239–1248 (2017).
- (101) Bodur, H. et al. Turkish league against rheumatism consensus report: recommendations for management of axial spondyloarthritis. *Arch. Rheumatol.* 33, 1–16 (2018).
- (102) Rohekar, S. et al. 2014 Update of the Canadian rheumatology association/ spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part II: specific management recommendations. *J. Rheuma.* 42, 665–681 (2015).
- (103) Rohekar, S. et al. 2014 update of the Canadian rheumatology association/ spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. *J. Rheuma.* 42, 654–664 (2015).
- (104) National Institute for Health and Care Excellence. Spondyloarthritis in Over 16s: Diagnosis and Management. (National Institute for Health and Care Excellence, UK, 2017).
- (105) Ward, M. M. et al. American college of rheumatology/spondylitis association of america/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheuma.* 68, 282–298 (2016).
- (106) van der Heijde, D. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann. Rheum. Dis.* 76, 978–991 (2017).
- (107) Dagfinrud, H., Kvien, T. K. & Hagen, K. B. The cochrane review of physiotherapy interventions for ankylosing spondylitis. *J. Rheuma.* 32, 1899–1906 (2005).
- (108) Dulger, S. et al. How does smoking cessation affect disease activity, function loss, and quality of life in smokers with ankylosing spondylitis? *J. Clin. Rheumatol.* <https://doi.org/10.1097/RHU.0000000000000851> (2018).
- (109) Smolen, J. S. et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann. Rheum. Dis.* 77, 3–17 (2018).
- (110) Sieper, J. et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). *Ann. Rheum. Dis.* 75, 1438–1443 (2016)
- (111) Kroon, F., Landewe, R., Dougados, M. & van der Heijde, D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. *Ann. Rheum. Dis.* 71, 1623–1629 (2012).
- (112) Wanders, A. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. *Arthritis Rheum.* 52, 1756–1765 (2005).
- (113) Sieper, J. et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, p
- (114) Gao, X. et al. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. *J. Med. Econ.* 15, 1054–1063 (2012)
- (115) obo-Ibanez, T., Ordonez, M. D. C., Munoz-Fernandez, S., Madero-Prado, R. & Martin-Mola, E. Do TNF-blockers reduce or induce uveitis? *Rheumatology* 47, 731–732 (2008).
- (116) Deodhar, A. & Yu, D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. *Semin. Arthritis Rheu.* 47, 343–350 (2017).
- (117) Lie, E. et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. *Ann. Rheum. Dis.* 70, 157–163 (2011).
- (118) Cantini, F., Niccoli, L., Cassara, E., Kaloudi, O. & Nannini, C. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. *Biologics* 7, 1–6 (2013)
- (119) van Royen, B. J. & de Gast, A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. *Ann. Rheum. Dis.* 58, 399–406 (1999).
- (120) Haibel, H. et al. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. *Ann. Rheum. Dis.* 73, 243–246 (2014)

- (121) Baraliakos, X. et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. *J. Rheuma.* 34, 510–515 (2007).
- (122) Ravindran, V., Scott, D. L. & Choy, E. H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. *Ann. Rheum. Dis.* 67, 855–859 (2008).
- (123) Kubiak, E. N., Moskovich, R., Errico, T. J. & Di Cesare, P. E. Orthopaedic management of ankylosing spondylitis. *J. Am. Acad. Orthop. Surg.* 13, 267–278 (2005)
- (124) Allouch, H., Shousha, M. & Böhm, H. Operationen bei ankylosierender spondylitis (morbus bechterew). *Z. Rheumatol.* 76, 848–859 (2018).
- (125) Qian, B. P., Mao, S. H., Jiang, J., Wang, B. & Qiu, Y. Mechanisms, predisposing factors, and prognosis of intraoperative vertebral sublaxation during pedicle subtraction osteotomy in surgical correction of thoracolumbar kyphosis secondary to ankylosing spondylitis. *Spine* 42, E983–E990 (2016).
- (126) He, A. et al. One-stage surgical treatment of cervical spine fracture-dislocation in patients with ankylosing spondylitis via the combined anterior-posterior approach. *Medicine* 96, e7432 (2017)
- (127) Ji, M. et al. Change in abdominal morphology after surgical correction of thoracolumbar kyphosis secondary to ankylosing spondylitis: a computed tomographic study. *Spine* 40, 1244–1249 (2015).
- (128) Lin, B., Zhang, B., Li, Z. & Li, Q. Corrective surgery for deformity of the upper cervical spine due to ankylosing spondylitis. *Indian J. Orthop.* 48, 211–215 (2014).
- (129) Kiaer, T. & Gehrchen, M. Transpedicular closed wedge osteotomy in ankylosing spondylitis: results of surgical treatment and prospective outcome analysis. *Eur. Spine J.* 19, 57–64 (2010)
- (130) Etame, A. B., Than, K. D., Wang, A. C., La, M. F. & Park, P. Surgical management of symptomatic cervical or cervicothoracic kyphosis due to ankylosing spondylitis. *Spine* 33, 559–564 (2008).
- (131) Koller, H., Mayer, M., Hempfing, A. & Koller, J. Osteotomies in ankylosing spondylitis: where, how many, and how much? *Eur. Spine J.* 27, 70–100 (2018).
- (132) La Chapelle, E. H. Osteotomy of the lumbar spine for correction of kyphosis in a case of ankylosing spondylarthritis. *J. Bone Jt. Surg. Am.* 28, 851–858 (1946).
- (133) Goel, M. K. Vertebral osteotomy for correction of fixed flexion deformity of the spine. *J. Bone Jt. Surg. Am.* 50, 287–294 (1968)
- (134) Klems, H. & Friedebold, G. Rupture of the abdominal aorta following a corrective spinal operation for ankylopoetic spondylitis. *Z. Orthop. Ihre Grenzgeb.* 108, 554–563 (1971).
- (135) Weatherley, C., Jaffray, D. & Terry, A. Vascular complications associated with osteotomy in ankylosing spondylitis: a report of two cases. *Spine* 13, 43–46 (1988).
- (136) van Royen, B. J., de Kleuver, M. & Slot, G. H. Polysegmental lumbar posterior wedge osteotomies for correction of kyphosis in ankylosing spondylitis. *Eur. Spine J.* 7, 104–110 (1998).
- (137) Hehne, H. J., Zielke, K. & Bohm, H. Polysegmental lumbar osteotomies and transpedicled fixation for correction of long-curved kyphotic deformities in ankylosing spondylitis. *Rep. 177 cases. Clin. Orthop. Relat. Res.* 258, 49–55 (1990).
- (138) Halm, H., Metz-Stavenhagen, P., Schmitt, A. & Zielke, K. Surgical treatment of kyphotic spinal deformities in ankylosing spondylitis using the Harrington compression system: long-term results based on the MOPO scales in the framework of a retrospective questionnaire. *Z. Orthop. Ihre Grenzgeb.* 133, 141–147 (1995).
- (139) Scudese, V. A. & Calabro, J. J. Vertebral wedge osteotomy. Correction of rheumatoid (ankylosing) spondylitis. *JAMA* 186, 627–631 (1963).
- (140) Ziwan, J. L. The treatment of flexion deformities of the spine in Bechterew disease. *Beitr. Orthop. Traumatol.* 29, 195–199 (1982).
- (141) Thomasen, E. Vertebral osteotomy for correction of kyphosis in ankylosing spondylitis. *Clin. Orthop. Relat. Res.* 194, 142–152 (1985).
- (142) Thiranont, N. & Netrawichien, P. Transpedicular decancellation closed wedge vertebral osteotomy for treatment of fixed flexion deformity of spine in ankylosing spondylitis. *Spine* 18, 2517–2522 (1993).
- (143) Ea, H. K., Liote, F., Lot, G. & Bardin, T. Cauda equina syndrome in ankylosing spondylitis: successful treatment with lumboperitoneal shunting. *Spine* 35, E1423–E1429 (2010).

- (144) Ahn, N. U. et al. Cauda equina syndrome in ankylosing spondylitis (the CES-AS syndrome): meta-analysis of outcomes after medical and surgical treatments. *J. Spinal Disord.* 14, 427–433 (2001).
- (145) Vander, C. B. et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. *Rheumatology* 49, 73–81 (2010).
- (146) Xu, J., Zeng, M., Xie, J., Wen, T. & Hu, Y. Cementless total hip arthroplasty in patients with ankylosing spondylitis: a retrospective observational study. *Medicine* 96, e5813 (2017)
- (147) He, C. et al. The effect of total hip replacement on employment in patients with ankylosing spondylitis. *Clin. Rheuma.* 35, 2975–2981 (2016).
- (148) Feng, D. X. et al. Bilaterally primary cementless total hip arthroplasty for severe hip ankylosis with ankylosing spondylitis. *Orthop. Surg.* 8, 352–359 (2016)
- (149) Ye, C. et al. Cementless bilateral synchronous total hip arthroplasty in ankylosing spondylitis with hip ankylosis. *Int. Orthop.* 38, 2473–2476 (2014).
- (150) Xu, B. G. et al. Medium-term follow-up outcomes of total hip arthroplasty for patients with ankylosing spondylitis. *Zhongguo Gu Shang* 26, 1052–1056 (2013)
- (151) Bisla, R. S., Ranawat, C. S. & Inglis, A. E. Total hip replacement in patients with ankylosing spondylitis with involvement of the hip. *J. Bone Jt. Surg. Am.* 58, 233–238 (1976).
- (152) Tang, W. M. & Chiu, K. Y. Primary total hip arthroplasty in patients with ankylosing spondylitis. *J. Arthroplast.* 15, 52–58 (2000)
- (153) Bangjian, H., Peijian, T. & Ju, L. Bilateral synchronous total hip arthroplasty for ankylosed hips. *Int. Orthop.* 36, 697–701 (2012)
- (154) Zheng, G. Q., Zhang, Y. G., Chen, J. Y. & Wang, Y. Decision making regarding spinal osteotomy and total hip replacement for ankylosing spondylitis: experience with 28 patients. *Bone Jt. J.* 96-B, 360–365 (2014).
- (155) Kim, K. T. et al. Surgical treatment of "chin-on-pubis" deformity in a patient with ankylosing spondylitis: a case report of consecutive cervical, thoracic, and lumbar corrective osteotomies. *Spine* 37, E1017–E1021 (2012)
- (156) Boonen, A. Socioeconomic consequences of ankylosing spondylitis. *Clin. Exp. Rheumatol.* 20, S23–S26 (2002).